A. Scherpereel (Lille, France), I. Kalomenidis (Marousi, Greece)
LATE-BREAKING ABSTRACT: A new treatment combining valproate acid (VA) plus doxorubicin (D) for patients with refractory or recurrent malignant mesothelioma (MM): a phase II study
A. S. Scherpereel, T. B. Berghmans, L. W. Willems, M. P. Paesmans, B. C. Chahine, A. P. M. Meert, N. L. Leclercq, F. V. Vandermeers, J. J. L. Lafitte, J. P. S. Sculier (Lille, France; Brussels, Gembloux, Belgium)
|   |
Species specific intercellular signalling pathway in human and rat mesothelioma cells
J. Zhong, M. Tamm, D. Lardinois, M. Roth (Basel, Switzerland)
|  |
The inhibitory effect of peroxisome proliferator activated receptor-γ ligands on malignant pleural mesothelioma cell growth
N. Hamaguchi, H. Hamada, S. Miyoshi, R. Ito, J. Higaki (Toon, Japan)
| |
Cytotoxic lymphocytes show reduced expression of CD94/NKG2A and perforin in malignant pleural effusions
E. Pace, C. Di Sano, A. Tipa, M. Ferraro, D. Olivieri, M. Spatafora, R. Santagata, V. Bellia, M. Gjomarkaj (Palermo, Parma, Italy)
| |
Elevated IL-18 levels in exudative pleural effusions, correlation with markers of pleural inflammation
N. Rovina, E. Dima, I. Psallidas, C. Gerassimou, A. Kollintza, C. Roussos, I. Kalomenidis (Athens, Greece)
| |
Monoclonal antibody anti-TGFb1 inhibits pleurodesis by silver nitrate
E. Marchi, F. Vargas, R. Takemura, M. Acencio, E. Genofre, L. Antonangelo, L. Teixeira (Sao Paulo, Brazil)
| |
Soluble mesothelin as a monitoring tool for malignant mesothelioma patients
K. Hollevoet, E. Kellen, K. Nackaerts, L. Bosqueé, P. Germonpré, J. Delanghe, C. Legrand, J. P. van Meerbeeck (Ghent, Leuven, Liège, Antwerp, Louvain-la-Neuve, Belgium)
| |
Pleurodesis after intrapleural catheter insertion is an independent factor for overall survival in patients with malignant pleural effusions
C. A. Jimenez, B. Ozcakar, R. C. Morice, G. A. Eapen, R. F. Casal, H. T. Chiu, M. F. Munsell, C. L. Warneke, C. H. Martinez (Houston, Galveston, Dallas, United States Of America)
| |